高强度聚焦超声联合白蛋白结合型紫杉醇治疗胰腺癌临床疗效观察被引量：3

The clinical efficiency of combination treatment of high-intensity focused ultrasound and nab-paclitaxel in patients with pancreatic cancer

下载PDF

导出

摘要目的探讨高强度聚焦超声（high-intensity focused ultrasound,HIFU）联合白蛋白结合型紫杉醇治疗晚期胰腺癌临床疗效及不良反应情况。方法将38例无法手术切除的胰腺癌患者随机分为治疗组20例和对照组18例。对照组：单纯行白蛋白结合型紫杉醇治疗。治疗组：先行2个周期白蛋白结合型紫杉醇治疗,再行HIFU治疗。评价指标为：肿瘤客观疗效、疼痛缓解程度、生存期及不良反应发生情况。结果治疗组总体有效率、疼痛缓解率及中位生存期分别为75.0%、90.0%和4.5个月,均明显优于对照组（50.0%、44.4%和9.5个月）,差异有统计学意义（P〈0.001）。两组均无Ⅲ~Ⅳ级不良反应发生。结论 HIFU联合白蛋白结合型紫杉醇治疗晚期胰腺癌可明显缓解癌性疼痛、改善生活质量、延长生存期,且具有安全性高的优点,值得临床推广。 Objective To investigate the clinical efficiency and adverse reactions of combination treatment of high- intensity focused ultrasound （HIFU） and nab-paclitaxel in patients with pancreatic cancer. Methods Thirty-eight pa- tients with unresectable pancreatic cancer were randomly divided into treatment group （20 cases） and control group （ 18 cases）. Combination HIFU with nab-paclitaxel treatment was given treatment group and signal nab-paelitaxel treatment was given control group. Clinical curative effect, pain remission rate, survival and adverse reactions were evaluated. Results The total effectiveness, pain remission rate and median survival were 75.0% , 90.0% and 14.5 months in treatment group, which were better than those in control group （50.0% , 44.4% and 9.5 months）（ P 〈0 . 001 ）. There was no Ⅲ - Ⅳadverse reactions in the two groups. Conclusion The combination treatment of HIFU and nab-paclitaxel is a feasible, safe, effective method for patients with pancreatic cancer.

作者李鑫郝冬兰黄河清门永忠

机构地区邓州仁爱医院肿瘤科解放军总医院介入超声科邓州市中心医院超声科南阳市中心医院超声科

出处《胃肠病学和肝病学杂志》 CAS 2015年第8期1000-1002,共3页 Chinese Journal of Gastroenterology and Hepatology

关键词胰腺癌高强度聚焦超声白蛋白结合型紫杉醇 Pancreatic cancer High-intensity focused ultrasound Nab-paclitaxel

分类号 R735.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 64(1) : 9-29.
2Long J, Luo GP, Xiao ZW, et al. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai,China [J]. Cancer Lett, 2014, 346(2) : 273-277.
3Vincent A, Herman J, Schulick R, et al. Pancreatic cancer [J]. Lancet, 2011, 378(9791) : 607-620.
4Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009,45(2) : 228-247.
5NCI Guidelines: Adverse Event Reporting Requirements [C]. Cancer Therapy Evaluation Program , 2013.
6Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials [J]. Eur J Cancer, 2013 , 49(3): 593-603.
7黄少江.白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌的临床观察[J].国际肿瘤学杂志,2014,41(8):620-623. 被引量：6
8Yardley DA. Nab-Paclitaxel mechanisms of action and delivery [J]. J Control Release, 2013, 28,170(3) : 365-372.
9Zhang DS, Wang DS, Wang ZQ , et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer [J]. Cancer Chemother Pharmacol, 2013,71(4) ; 1065-1072.
10Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer [J]. Br J Cancer, 2013,109(4) : 926-933.

二级参考文献9

1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J].CA Cancer J Clin.2013, 63(1):11-30.
2Li D, Xie K, Wolff R, et al. Pancreatic cancer[J].Lancet.2004, 363(9414):1049-1057.
3Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albuminbound paclitaxel, ABI007, compared with cremophorbased paclitaxel[J].Clin Cancer Res.2006, 12(4):1317-1324.
4Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase Ⅰ/Ⅱtrial[J].J Clin Oncol.2011, 29(34):4548-4554.
5Daniel D, Von Hoff, Thomas J, et al. Results of a randomized phase trial (MPACT) of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA199 correlates[J]. J Clin Oncol, 2013, 31 Supple: abstr4005.
6Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol.2007, 25(15):1960-1966.
7Calvani M, Trisciuoglio D, Bergamaschi C, et al. Differential involvement of vascular endothelial growth factor in the survival of hy- poxic colon cancer cells [J]. Cancer Res, 2008, 68(1): 285-291.
8Bockhorn M, Tsuzuki Y, Xu L, et al. Differential vascular and transcriptional responses to antivascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts[J]. Clin Cancer Res, 2003, 9(11): 4221-4226.
9Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase Ⅲ trial of the Cancer and Leukemia Group B (CALGB 80303)[J].J Clin Oncol.2010, 28(22):3617-3622.